ANALYSIS OF NICE AND US ICER HTA OUTCOMES FOR ULTRA-ORPHAN MEDICINAL PRODUCTS

被引：0
|
作者：
Dusza, M. [1 ]
Kloc, K. [1 ]
Remuzat, C. [2 ]
Francois, C. [3 ]
Toumi, M. [3 ]
机构：
[1] Creativ Ceut, Krakow, Poland
[2] Creativ Ceut, Lyon, France
[3] Aix Marseille Univ, Marseille, France
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO108
引用
收藏
页码：S861 / S861
页数：1
相关论文
共 35 条
  • [1] ULTRA-ORPHAN MEDICINAL PRODUCTS ASSESSMENT: COMPARISON OF THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND THE INSTITUTE OF CLINICAL AND ECONOMIC REVIEW (ICER) HTA FRAMEWORKS
    Dusza, M.
    Kloc, K.
    Remuzat, C.
    Francois, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S859 - S859
  • [2] AN ANALYSIS OF ULTRA-ORPHAN INITIAL ASSESSMENTS IN SCOTLAND COMPARED WITH OTHER KEY EUROPEAN HTA AGENCIES
    Foster, D.
    Walker, S.
    Phalguni, A.
    Jones, G.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S178 - S178
  • [3] GLOBAL HTA ASSESSMENTS OF ULTRA-ORPHAN PRODUCTS: A CASE STUDY OF ECULIZUMAB (SOLIRIS) AND IDURONATE-2-SULFATASE (ELAPRASE)
    Paul, A.
    Morawski, J.
    Spinner, D. S.
    Doyle, J. J.
    Faulkner, E. C.
    Ransom, J. F.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A431 - A431
  • [4] THE NEW SMC ULTRA-ORPHAN PATHWAY: HTA BEST PRACTICE FOR VERY RARE DISEASES?
    Carr, D.
    Macaulay, R.
    [J]. VALUE IN HEALTH, 2021, 24 : S241 - S241
  • [5] A COMPARATIVE REVIEW OF NICE AND SMC DECISION-MAKING FOR ULTRA-ORPHAN MEDICINES
    Gibbs, K. L.
    Schmetz, A.
    Emich, H.
    Gardner, K.
    [J]. VALUE IN HEALTH, 2019, 22 : S861 - S861
  • [6] MARKET ACCESS AND PRICING ANALYSIS OF ULTRA-ORPHAN DRUGS
    Malacan, J.
    Gabriel, S.
    Dinet, J.
    Forget, S.
    Borget, I
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
  • [7] IS ULTRA-ORPHAN DISEASE TREATMENT ACCESS EQUITABLE IN THE UK? COMPARISON BETWEEN SMC AND NICE HST GUIDANCE
    Tang, M.
    Samuels, E.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S186 - S186
  • [8] ANALYSIS OF THE ULTRA-ORPHAN DRUGS APPROVED BY THE FDA IN THE PERIOD 1983-2014
    Thumar, R.
    Seoane-Vazquez, E.
    Mantus, D.
    Tyrrell, B.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A255 - A255
  • [9] Ultra-orphan diseases: a quantitative analysis of the natural history of molybdenum cofactor deficiency
    Mechler, Konstantin
    Mountford, William K.
    Hoffmann, Georg F.
    Ries, Markus
    [J]. GENETICS IN MEDICINE, 2015, 17 (12) : 965 - 970
  • [10] DOES ORPHAN DRUG STATUS CONFER ANY BENEFITS FOR PRODUCTS UNDERGOING HTA APPRAISAL BY NICE IN ENGLAND?
    Foxon, G.
    Craddy, P.
    Wilson, C.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S180 - S180
1234